<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification of select antiretroviral agents (agents within class listed alphabetically)*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification of select antiretroviral agents (agents within class listed alphabetically)*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Classification of select antiretroviral agents (agents within class listed alphabetically)*</div><div class="cntnt"><table cellspacing="0"><colgroup width="65%"></colgroup><colgroup width="35%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug (abbreviations)</td> <td class="subtitle1">Brand name in the United States</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)</td> </tr> <tr> <td class="indent1">Abacavir (ABC)</td> <td>Ziagen</td> </tr> <tr> <td class="indent1">Emtricitabine (FTC)</td> <td>Emtriva</td> </tr> <tr> <td class="indent1">Lamivudine (3TC)</td> <td>Epivir</td> </tr> <tr> <td class="indent1">Stavudine (d4T)</td> <td>Zerit<sup>¶</sup></td> </tr> <tr> <td class="indent1">Tenofovir alafenamide (TAF)</td> <td>Vemlidy</td> </tr> <tr> <td class="indent1">Tenofovir disoproxil fumarate (TDF)</td> <td>Viread</td> </tr> <tr> <td class="indent1">Zidovudine (ZDV, AZT)</td> <td>Retrovir</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</td> </tr> <tr> <td class="indent1">Doravirine (DOR)</td> <td>Pifeltro</td> </tr> <tr> <td class="indent1">Efavirenz (EFV)</td> <td>Sustiva</td> </tr> <tr> <td class="indent1">Etravirine (ETR)</td> <td>Intelence</td> </tr> <tr> <td class="indent1">Nevirapine (NVP)</td> <td>Viramune, Viramune XR<sup>¶</sup></td> </tr> <tr> <td class="indent1">Rilpivirine (RPV)</td> <td>Edurant</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Protease inhibitors (PIs)</td> </tr> <tr> <td class="indent1">Atazanavir (ATV)</td> <td>Reyataz</td> </tr> <tr> <td class="indent1">Atazanavir-cobicistat (ATV/COBI)</td> <td>Evotaz</td> </tr> <tr> <td class="indent1">Darunavir (DRV)</td> <td>Prezista</td> </tr> <tr> <td class="indent1">Darunavir-cobicistat (DRV/COBI)</td> <td>Prezcobix</td> </tr> <tr> <td class="indent1">Fosamprenavir (FPV)</td> <td>Lexiva</td> </tr> <tr> <td class="indent1">Lopinavir/ritonavir boosting (LPV/r)</td> <td>Kaletra</td> </tr> <tr> <td class="indent1">Nelfinavir (NFV)</td> <td>Viracept</td> </tr> <tr> <td class="indent1">Ritonavir (RTV) (used as a pharmacokinetic boosting agent)</td> <td>Norvir</td> </tr> <tr> <td class="indent1">Tipranavir (TPV)</td> <td>Aptivus</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Fusion inhibitor</td> </tr> <tr> <td class="indent1">Enfuvirtide (T-20)</td> <td>Fuzeon</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Integrase strand transfer inhibitors (INSTIs)*</td> </tr> <tr> <td class="indent1">Cabotegravir (CAB; oral formulation)</td> <td>Vocabria</td> </tr> <tr> <td class="indent1">Dolutegravir (DTG)</td> <td>Tivicay, Tivicay PD</td> </tr> <tr> <td class="indent1">Raltegravir (RAL)</td> <td>Isentress, Isentress HD</td> </tr> <tr> <td class="subtitle2_left" colspan="2">CCR5 antagonist</td> </tr> <tr> <td class="indent1">Maraviroc (MVC)</td> <td>Selzentry</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Attachment inhibitor</td> </tr> <tr> <td class="indent1">Fostemsavir</td> <td>Rukobia</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Post-attachment inhibitor</td> </tr> <tr> <td class="indent1">Ibalizumab (IBA)</td> <td>Trogarzo</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Capsid inhibitor</td> </tr> <tr> <td class="indent1">Lenacapavir (LEN)</td> <td>Sunlenca</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Fixed-dose oral combinations</td> </tr> <tr> <td class="indent1">Abacavir-lamivudine (ABC/3TC)</td> <td>Epzicom</td> </tr> <tr> <td class="indent1">Abacavir-lamivudine-zidovudine (ABC/3TC/ZDV)</td> <td>Trizivir</td> </tr> <tr> <td class="indent1">Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF)</td> <td>Biktarvy</td> </tr> <tr> <td class="indent1">Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (DRV/COBI/FTC/TAF)</td> <td>Symtuza</td> </tr> <tr> <td class="indent1">Dolutegravir-abacavir-lamivudine (DTG/ABC/3TC)</td> <td>Triumeq, Triumeq PD</td> </tr> <tr> <td class="indent1">Dolutegravir-lamivudine (DTG/3TC)</td> <td>Dovato</td> </tr> <tr> <td class="indent1">Dolutegravir-rilpivirine (DTG/RPV)</td> <td>Juluca</td> </tr> <tr> <td class="indent1">Doravirine-lamivudine-tenofovir disoproxil fumarate (DOR/3TC/TDF)</td> <td>Delstrigo</td> </tr> <tr> <td class="indent1">Efavirenz-emtricitabine-tenofovir disoproxil fumarate (EFV/FTC/TDF)</td> <td>Atripla<sup>¶</sup></td> </tr> <tr> <td class="indent1">Efavirenz-lamivudine-tenofovir disoproxil fumarate (EFV/3TC/TDF)</td> <td>Symfi, Symfi Lo</td> </tr> <tr> <td class="indent1">Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide (ECF/TAF or EVG/COBI/FTC/TAF)</td> <td>Genvoya</td> </tr> <tr> <td class="indent1">Elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate (ECF/TDF or EVG/COBI/FTC/TDF)</td> <td>Stribild</td> </tr> <tr> <td class="indent1">Lamivudine-tenofovir disoproxil fumarate (3TC/TDF)</td> <td>Cimduo</td> </tr> <tr> <td class="indent1">Rilpivirine-emtricitabine-tenofovir alafenamide (RPV/FTC/TAF)</td> <td>Odefsey</td> </tr> <tr> <td class="indent1">Rilpivirine-emtricitabine-tenofovir disoproxil fumarate (RPV/FTC/TDF)</td> <td>Complera</td> </tr> <tr> <td class="indent1">Tenofovir alafenamide-emtricitabine (TAF/FTC)</td> <td>Descovy</td> </tr> <tr> <td class="indent1">Tenofovir disoproxil fumarate-emtricitabine (TDF/FTC)</td> <td>Truvada</td> </tr> <tr> <td class="indent1">Zidovudine-lamivudine (ZDV/3TC)</td> <td>Combivir</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Injectable combination</td> </tr> <tr> <td class="indent1">Cabotegravir-rilpivirine (CAB/RPV; extended-release injectable formulation)</td> <td>Cabenuva</td> </tr> </tbody></table></div><div class="graphic_lgnd">Brand names shown are for preparations available in United States and some other countries.</div><div class="graphic_footnotes"><p>* Some agents (eg, bictegravir, elvitegravir) are only available in fixed dose combinations and are listed in that category and not within their mechanistic class.</p>
¶ Only available generically.</div><div id="graphicVersion">Graphic 60927 Version 34.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
